HOME | SHORT COURSES | SPEAKERS | SPONSOR & EXHIBIT | POSTERS | HOTEL & TRAVEL | Download Brochure(PDF) | CONTACT | REGISTER

Premier Sponsor

Vivalis

View All Sponsors
View Media Partners

PEGS Summit 2012

30 April 2012
4 May 2012

Boston, USA

the essential protein engineering summit

Choose your language
Japanese
Traditional Chinese
Simplified Chinese
Korean

DOWNLOAD BROCHURE

2012 PEGS Brochure

2012 Final Brochure

Industry Event Calendar

ANTIBODIES STREAM

2nd Annual

Antibody-Drug Conjugates May 3 - 4

Antibody-drug conjugates (ADCs) in late-stage clinical development have shown encouraging therapeutic effects against both solid tumors and hematological malignancies. Significant progress has been made through optimization of parameters including specificity, potency, linker technology, conjugate site design, and the stoichiometry and placement of drugs. These sessions will showcase the design and discovery of next generation ADC's, leveraging current knowledge from successful clinical candidates.

Day 1 | Day 2

THURSDAY, MAY 3

12:00 pm Registration

THE NEXT GENERATION OF ADCS – LEARNING FROM THE CLINIC IN REAL TIME

1:30 Chairperson's Opening Remarks

Pamela A. Trail, Ph.D., Vice President, Oncology, Regeneron Pharmaceuticals, Inc.


» 1:40 Featured Speaker

Lessons Learned from the Clinic – T-DM1 and Beyond

John Lambert, Ph.D., CSO, ImmunoGen, Inc.

Since 1999, a number of antibody-maytansinoid conjugates (AMCs) have entered clinical testing, with the most advanced of these, T-DM1 and SAR3419, attracting attention for their efficacy and tolerability profile. Lessons learned from earlier AMCs helped inform the design of these compounds, and this body of knowledge that can be applied to AMC design continues to expand and will be discussed.

» 2:10 Featured Speaker

The Development of ADCs at Seattle Genetics

Jonathan Drachman, M.D., Senior Vice President, Research and Translational Medicine, Seattle Genetics

Antibody-drug conjugates (ADCs) represent an important class of new cancer therapeutics under development. The deceptively simple concept of targeted drug delivery has been an elusive goal for decades but has been realized with the approval of brentuximab vedotin (ADCETRIS).The current approach to designing empowered antibodies and testing them both pre-clinically and clinically will be discussed.

2:40 Sponsored Presentations (Opportunities Available)

3:10 Refreshment Break in the Exhibit Hall with Poster Viewing

4:00 Clinical Case Study

Anne Bousseau, M.D., Head, Early Development Projects, Global Oncology, Sanofi-Aventis

4:30 Antibody-Drug Conjugates: Pre-Clinical Evaluation of a Novel Target

Andrew Simmons, Ph.D., Associate Director, Oncology, Takeda California


5:30-8:30 pm Recommended Dinner Short Course*

SC14 Antibody Conjugate Therapeutics: Potential and Challenges

*Separate registration required.



Day 1 | Day 2

 

Cambridge Healthtech Institute  | Global Information, Inc. - International Marketing Partner of Cambridge Healthtech Institute.